PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers.

IF 4.8 2区医学 Q1 UROLOGY & NEPHROLOGY

European urology focus Pub Date : 2024-09-03 DOI:10.1016/j.euf.2024.08.005

Elena Castro

引用次数: 0

Abstract

For patients with metastatic castration-resistant prostate cancer whose tumors harbor BRCA1/2 alterations, the potential benefits of combining a PARP inhibitor and an androgen receptor pathway inhibitor for first-line treatment outweigh the potential side effects. Further research is required to identify patients without detectable BRCA1/2 defects who would benefit from this approach.

查看原文本刊更多论文

转移性抗性前列腺癌患者在使用雄激素受体通路抑制剂的同时使用 PARP 抑制剂，应仅限于 BRCA 基因突变携带者。

对于肿瘤携带 BRCA1/2 基因改变的转移性耐受性前列腺癌患者来说，将 PARP 抑制剂和雄激素受体通路抑制剂联合用于一线治疗的潜在益处大于潜在副作用。还需要进一步的研究来确定哪些未检测到 BRCA1/2 缺陷的患者可以从这种方法中获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology focus Medicine-Urology

CiteScore

10.40

自引率

3.70%

发文量

274

审稿时长

23 days

期刊介绍： European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU). EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.